Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER-MES: Head-to-head Study of Erenumab Against Topiramate in Migraine
NCT03828539Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of erenumab in migraine (2 arms), sponsored by Novartis. Primary endpoint: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event at 24 weeks. Started Feb 2019; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03828539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828539.